CRISPR and Cas Genes Market - Databook 2025 to 2034

The global CRISPR and cas genes market size was evaluated at USD 4,710 million in 2024 and is expected to grow around USD 21,140 million by 2034, registering a CAGR of 16.2% from 2025 to 2034.

CRISPR and Cas Genes Market Report Highlights

• North America dominated the CRISPR and Cas genes market in the year 2024.
• Europe is anticipated to grow at the fasts rate in the forecasted period of 2025-2034.
• By product and service, the product segment contributed to the major market share for the market in the year 2024.
• By product and service, the service segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By application, the biomedical applications segment dominated the market in 2024.
• By application, the agricultural segment is anticipated to register a significant CAGR over the forecast period.
• By end-use, the biotechnology and pharmaceutical companies segment accounted for the highest market share in the year 2024.
• By end-use, the Contract Research Organizations (CROs) segment is expected to have the fastest growth in the forecasted period of 2025-2034.

Industry Valuation and Growth Rate Projection

CRISPR is a gene-editing technology that helps scientists to edit the DNA of living things. It is derived from a naturally occurring bacterial immune system found in nature. The CRISPR-Cas9 system is faster, cheaper, effective, and more accurate than any other genome editing method. Researchers have chosen this method due to its efficiency and accuracy in editing DNA. A small RNA is created that binds to specific target sequences in a cell’s DNA. When it encounters the cells, the guide RNA recognizes the intended DNA sequence, and the Cas9 enzyme cuts the DNA at the targeted location.

The primary focus of CRISPR and Cas gene market dynamics is on gene-editing treatments with its potential to aid in genetic disorders, sickle cell anemia, cystic fibrosis, and muscular dystrophy. CRISPR is also being used in agricultural biotechnology to enhance crop yield, resistance to pets & environment stress, and drug discovery to provide more effective and accurate methods to validate drug targets.

CRISPR and Cas Genes Market: Stats and Figures

• The market is expected to grow steadily in the forecasted period 2025-2034 with a CAGR of 16.90%.
• The number of people having sickle cell diseases increased 41.4% between 2000 to 2021, with an increase from 5.46 million in 2020 to 7.74 million in 2021.
• In 2022, approximately 20 million new cancer cases were diagnosed worldwide, with projections estimating an increase to 35 million cases annually by 2050.
• The World Health Organization (WHO) forecasts a 77% rise in global cancer cases by 2050, escalating from 20 million new cases in 2022 to over 35 million.
• In 2022, nearly half of the new cancer cases occurred in Asia, which also accounted for a majority of the 9.7 million cancer deaths that year.

How AI has benefitted the CRISPR and Cas genes market

Artificial Intelligence (AI) has been a major game changer in the healthcare industry, helping in the research and development of products to fulfill market expectations and enhance success rates. Some advantages that AI brings into the market of CRISPR and Cas genes are:

• AI significantly enhances the efficiency, accuracy, and precision of CRISPR target sites with minimal off-target effects by analyzing the genomic datasets.
• AI helps in streamlining the research and development of the experimental process, thus increasing efficiency and reducing the cost of trial and error in gene editing.
• AI boosts CRISPR applications in the agricultural field and assists in product designing and engineering beneficial microbes.

Industry Leader Announcements

• Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutic said-

“Building on the success of CASGEVY’s launch, we continue to broaden our portfolio across oncology, autoimmune, and cardiometabolic indications. 2025 promises to be a milestone-rich year with clinical data updates across several programs spanning a range of indications. In parallel, we are continuously innovating on our platform with next-generation gene editing and delivery technologies, which have the potential to broaden our ability to address additional diseases with curative treatments.”

• Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex, on the day when CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, was authorized by the United Kingdom MHRA, said

“Today is a historic day in science and medicine: this authorization of CASGEVY in Great Britain is the first regulatory authorization of a CRISPR-based therapy in the world.”

Geographical Insights

The CRISPR and Cas genes market is growing at a rapid rate, and a major part of the market is captured by North America, with Europe showing the fastest growth in the forecasted period of 2025-2034.

North America

North America dominates the CRISPR and Cas gene market throughout the world, with the highest market share of 39% in 2024. The leading companies of the world in the CRISPR and Cas gene market are based in this region and use highly advanced tech for the research and development of products in the healthcare industry. Besides this, the government initiative and investment also boost the growth of the market along with various market research organizations that partake in improving research for such products.

Asia-Pacific

The Asia Pacific region is expected to show the fastest growth in the CRISPR and Cas genes market in the forecasted period of 2025-2034. Technological Advancements and an increase in investment in biotechnology drive the market for the region.

• China makes the majority contribution in the APAC region with its cutting-edge technology and advancements in biotechnology and increase in the investment and initiative from the government for research and development of genome editing practices. At present, China hosts the highest number of clinical trials, including CRISPR technology, across the globe. It also holds more than 858 publicly accessible CRISPR patent applications, particularly in agriculture and other sectors.

Europe

The CRISPR and cas gene market in Europe is increasing steadily with the increase in investment in agriculture biotechnology to focus on crop modification. The growing interest in precision medicine and gene-edited crops are the key market drivers for the region. An increase in collaboration between big players to develop CRISPR-based therapies supports gene editing and fosters innovation in the market.

Recent Developments in the CRISPR and Cas Genes Market:

• Scientists are exploring the CRISPR-Cas9 for its revolutionary gene-editing feature to treat cancer. The focus in using it in cancer photodynamic therapy (SCT) and stem cell treatment to reduce the resistance from cancer-causing stem cells and increase the accuracy and effectiveness.
• On April 11, 2023, Cellectis announced that a patient was dosed in France with its first in-house manufactured product candidate UCART22 and completed the 28-day dose limiting toxicity (DLT) period.

Competitive Landscape

The CRISPR and cas genes market is dominated by North America, with the leading companies also operating in the region. Furthermore, with the increase in awareness about the benefits of genome-editing methods a lot of Biotech companies are significantly growing and fighting for the market share. The top 3 companies that hold the major market share worldwide are:

• Company Name: Caribou Biosciences Inc
• Year of Incorporation: 2011
• Headquarters: Berkeley, California

Caribou Biosciences Inc. is a biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies with its patented chRDNA (CRISPR hybrid RNA-DNA) technology. Caribou Biosciences Inc is one of the key players in the CRISPR and Cas genes market with its hold in the North American region. The company recorded $ 9.99 million of revenue in the year 2024.

• Company Name: Editas Medicine Inc
• Year of Incorporation: 2013
• Headquarters: Cambridge, Massachusetts

Editas Medicine Inc is a pioneering biotechnology company that is focused on developing transformative medicine and advanced therapies using CRISPR gene editing technology, with its main focus towards the vivo editing in hematopoietic stem cells, the liver, and other tissues. The country has gained a huge market share over the years in the North American region, with a revenue of $32.314 million in the year 2024.

• Company Name: Cellectis
• Year of Incorporation: 1999
• Headquarters: Paris, France

Cellectis is a clinical stage biopharmaceutical company with an expertise of gene editing for the past 25 years specializing in its TALEN technology to develop cell and gene therapies. Cellectis is one of the few companies that have in-house manufacturing to develop new and innovative therapeutic ideas.